종합 대사 패널 검사 시장 : 검사 유형별, 적응 질환별, 최종사용자별 : 세계 기회 분석과 산업 예측(2023-2032년)

The comprehensive metabolic panel testing market was valued at $10.1 billion in 2022 and is projected to reach $16.1 billion by 2032, registering a CAGR of 4.8% from 2023 to 2032. The comprehensive metabolic panel (CMP) is a blood test that measures several substances in the blood. The comprehensive metabolic panel test measures glucose levels, which indicates the level of sugar in the blood and is used to diagnose diabetes or monitor existing cases. In addition, CMP tests include testing of electrolytes such as sodium, potassium and chloride, which are crucial in maintaining fluid balance and carrying out proper nerve and muscle function such as contractility.

Furthermore, CMP studies kidney operations through determination of varying amounts of urea nitrogen (BUN) and creatinine in individual's blood contributes early detection of renal problems which drives the demand for CMP testing and supports market growth. For instance, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both examine liver health by indicating damage or illness occurrence within it. Overall, a comprehensive metabolic panel provides a comprehensive overview of key physiological processes, aiding healthcare professionals in diagnosing and managing various medical conditions.

Factors driving the growth of the comprehensive metabolic panel testing market include increased demand for diagnostic services and chronic conditions such as diabetes, cardiovascular diseases, and stroke that require accurate equipment timely diagnostic tools such as CMP testing essential. For instance, according to the Centers for Disease Control and Prevention (CDC), by 2022, 6 out of 10 adults in the U.S. had diabetes. Thus, the rise in prevalence of conditions such as diabetes, cardiovascular diseases, and kidney diseases requires regular biopsies, which drives the growth of the market.

In addition, rise in health care awareness and screening programs contribute significantly to the need for comprehensive metabolic panel (CMP) test. As preventive healthcare becomes more important in public health initiatives, they have become key components in educating people on the benefits of routine check-ups. These schemes promote early recognition and intervention, thus cultivating proactive management practices regarding healthcare, which fuels market growth. Furthermore, the shift toward preventive healthcare is a key factor driving the comprehensive metabolic panel testing market growth. As healthcare evolves, with a surge in emphasis on prompt healthcare and early diagnosis, this trend encourages individuals to adopt regular health screenings, prioritizing the identification of potential health risks before they manifest in more severe situations, thereby driving market growth.

Moreover, the growing elderly population demands the need for health care and diagnostic testing. Older individuals often require more frequent health check-ups with a comprehensive metabolic program to monitor their overall health and manage chronic conditions as older people are more likely to develop chronic conditions such as diabetes, heart disease and kidney disease. Comprehensive histology, which provides comprehensive biochemical information, is important in maintaining the health of older people and managing these conditions.

However, a lack of awareness among both individuals and healthcare providers poses a significant obstacle to the expansion of the comprehensive metabolic panel testing sector. In addition, stringent regulatory requirements and compliance standards in the healthcare business provide difficulties for laboratories and diagnostic service providers thereby hampering market growth. In contrast, the expansion of point-of-care testing allows for rapid on-site results, providing convenience and quick decision-making for healthcare professionals. Developing and adopting CMP testing as part of point-of-care solutions, particularly in decentralized healthcare settings, provides lucrative opportunity for market growth.

The comprehensive metabolic panel testing market is segmented on the basis of test type, disease indication, end user, and region. By test type, the market is classified into proteins, electrolytes, kidney tests, liver test, and others. By disease indication the market is categorized into kidney diseases, liver diseases, diabetes, and others. By end user, it is segregated into hospitals, diagnostic laboratories, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the comprehensive metabolic panel testing market are Quest Diagnostics, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Blueprint Genetics, ARUP Laboratories, Walk-In Lab, LLC., Applied InGENuity Diagnostics, Scion Lab Services, LLC, Baptist Health, and My Care Labs. Key players have adopted acquisition, product approval and product launch as key developmental strategies to improve the product portfolio of the comprehensive metabolic panel testing market.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the comprehensive metabolic panel testing market analysis from 2022 to 2032 to identify the prevailing comprehensive metabolic panel testing market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the comprehensive metabolic panel testing market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global comprehensive metabolic panel testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Test Type

• Proteins
• Electrolytes
• Kidney Tests
• Liver Tests
• Others

By Disease Indication

• Kidney Diseases
• Liver Diseases
• Diabtes
• Others

By End User

• Hospitals
• Diagnostic Laboratories
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest Of La
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• Quest Diagnostics
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche Ltd.
• ARUP Laboratories
• Walk-In Lab, LLC.
• Applied InGENuity Diagnostics
• Scion Lab Services, LLC
• Baptist Health
• My Care Labs
• Blueprint Genetics

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Proteins
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Electrolytes
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Kidney Tests
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Liver Tests
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Others
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Kidney Diseases
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Liver Diseases
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Diabetes
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Diagnostic Laboratories
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Test Type
  • 7.2.3. Market size and forecast, by Disease Indication
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Test Type
    • 7.2.5.1.2. Market size and forecast, by Disease Indication
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Test Type
    • 7.2.5.2.2. Market size and forecast, by Disease Indication
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Test Type
    • 7.2.5.3.2. Market size and forecast, by Disease Indication
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Test Type
  • 7.3.3. Market size and forecast, by Disease Indication
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Test Type
    • 7.3.5.1.2. Market size and forecast, by Disease Indication
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Test Type
    • 7.3.5.2.2. Market size and forecast, by Disease Indication
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Test Type
    • 7.3.5.3.2. Market size and forecast, by Disease Indication
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Test Type
    • 7.3.5.4.2. Market size and forecast, by Disease Indication
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Test Type
    • 7.3.5.5.2. Market size and forecast, by Disease Indication
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Test Type
    • 7.3.5.6.2. Market size and forecast, by Disease Indication
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Test Type
  • 7.4.3. Market size and forecast, by Disease Indication
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Test Type
    • 7.4.5.1.2. Market size and forecast, by Disease Indication
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Test Type
    • 7.4.5.2.2. Market size and forecast, by Disease Indication
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Test Type
    • 7.4.5.3.2. Market size and forecast, by Disease Indication
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Test Type
    • 7.4.5.4.2. Market size and forecast, by Disease Indication
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Test Type
    • 7.4.5.5.2. Market size and forecast, by Disease Indication
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Test Type
    • 7.4.5.6.2. Market size and forecast, by Disease Indication
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. Latin America
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Test Type
  • 7.5.3. Market size and forecast, by Disease Indication
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Test Type
    • 7.5.5.1.2. Market size and forecast, by Disease Indication
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Colombia
    • 7.5.5.2.1. Market size and forecast, by Test Type
    • 7.5.5.2.2. Market size and forecast, by Disease Indication
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Argentina
    • 7.5.5.3.1. Market size and forecast, by Test Type
    • 7.5.5.3.2. Market size and forecast, by Disease Indication
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest Of La
    • 7.5.5.4.1. Market size and forecast, by Test Type
    • 7.5.5.4.2. Market size and forecast, by Disease Indication
    • 7.5.5.4.3. Market size and forecast, by End User
• 7.6. Middle East and Africa
  • 7.6.1. Key market trends, growth factors and opportunities
  • 7.6.2. Market size and forecast, by Test Type
  • 7.6.3. Market size and forecast, by Disease Indication
  • 7.6.4. Market size and forecast, by End User
  • 7.6.5. Market size and forecast, by country
    • 7.6.5.1. Gcc
    • 7.6.5.1.1. Market size and forecast, by Test Type
    • 7.6.5.1.2. Market size and forecast, by Disease Indication
    • 7.6.5.1.3. Market size and forecast, by End User
    • 7.6.5.2. South Africa
    • 7.6.5.2.1. Market size and forecast, by Test Type
    • 7.6.5.2.2. Market size and forecast, by Disease Indication
    • 7.6.5.2.3. Market size and forecast, by End User
    • 7.6.5.3. North Africa
    • 7.6.5.3.1. Market size and forecast, by Test Type
    • 7.6.5.3.2. Market size and forecast, by Disease Indication
    • 7.6.5.3.3. Market size and forecast, by End User
    • 7.6.5.4. Rest Of Mea
    • 7.6.5.4.1. Market size and forecast, by Test Type
    • 7.6.5.4.2. Market size and forecast, by Disease Indication
    • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Quest Diagnostics
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Laboratory Corporation of America Holdings
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. F. Hoffmann-La Roche Ltd.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. ARUP Laboratories
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Walk-In Lab, LLC.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Applied InGENuity Diagnostics
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Scion Lab Services, LLC
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Baptist Health
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. My Care Labs
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Blueprint Genetics
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments